An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C

Trial Profile

An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Oct 2013 Planned End Date changed from 1 Mar 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top